|
Market Closed -
Bombay S.E.
13:02:27 13/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 507.55 INR | -0.37% |
|
+13.66% | +23.24% |
| 11-04 | Aarti Drugs Limited, Q2 2027 Earnings Call, Nov 04, 2026 | |
| 11-03 | Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 | CI |
| Market Cap | 46.32B 491M 445M 412M 372M 700M 725M 4.95B 1.96B 24.75B 1.84B 1.8B 78.55B | P/E 2027 * |
-
| P/E 2028 * | 16.2x |
|---|---|---|---|---|---|
| Enterprise Value | 46.32B 491M 445M 412M 372M 700M 725M 4.95B 1.96B 24.75B 1.84B 1.8B 78.55B | EV / Sales 2027 * |
1.52x | EV / Sales 2028 * | 1.39x |
| Free-Float |
40.8% | Yield 2027 * |
1.4% | Yield 2028 * | 1.54% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| AARTIDRUGS | Delayed | |
NSE India S.E.
| AARTIDRUGS | Delayed |
Last Transcript: Aarti Drugs Limited
| 28/12/22 | Aarti Drugs : Loss of Share Certificates | PU |
| 10/07/22 | Aarti Drugs : Newspaper Advertisements | PU |
| 1 day | -0.37% | ||
| 1 week | +13.66% | ||
| Current month | +16.49% | ||
| 1 month | +26.63% | ||
| 3 months | +21.70% | ||
| 6 months | +39.84% | ||
| Current year | +23.24% |
| 1 week | 446.1 |  | 527.85 |
| 1 month | 369 | | 527.85 |
| Current year | 318.6 | | 527.85 |
| 1 year | 318.6 | | 527.85 |
| 3 years | 312.5 | | 634.9 |
| 5 years | 310.8 | | 645 |
| 10 years | 104.82 | | 1,025 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 80 | - | |
| Chief Tech/Sci/R&D Officer | - | - | |
| Compliance Officer | - | 23/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 01/06/2007 | |
| Chairman | 80 | - | |
| Director/Board Member | 64 | 02/01/1987 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.37% | +13.66% | +9.47% | +5.55% | 491M | |
| +1.26% | +6.61% | +40.79% | +136.32% | 1,286B | |
| +0.79% | +3.45% | +45.84% | +93.52% | 688B | |
| +0.20% | +1.28% | +26.97% | +113.70% | 521B | |
| -0.44% | +3.69% | +41.45% | +68.91% | 386B | |
| +0.55% | +0.70% | +59.02% | +44.62% | 364B | |
| -0.12% | +0.74% | +28.39% | +58.54% | 302B | |
| +0.37% | +0.37% | +3.33% | +37.27% | 287B | |
| -0.30% | +1.14% | +38.29% | +72.46% | 252B | |
| +0.08% | +0.71% | +34.44% | +124.95% | 208B | |
| Average | +0.20% | +3.24% | +32.80% | +75.58% | 429B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.69% | +96.49% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 30.48B 323M 293M 271M 244M 461M 477M 3.25B 1.29B 16.28B 1.21B 1.19B 51.68B | 33.37B 354M 321M 297M 268M 504M 522M 3.56B 1.41B 17.83B 1.33B 1.3B 56.59B |
| Net income | 2.58B 27.41M 24.83M 22.97M 20.73M 39.06M 40.43M 276M 109M 1.38B 103M 101M 4.38B | 2.85B 30.27M 27.43M 25.37M 22.89M 43.14M 44.66M 305M 121M 1.52B 114M 111M 4.84B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | ₹507.55 | -0.37% | 118,927 |
| 12/11/26 | ₹509.45 | +3.57% | 67,976 |
| 11/11/26 | ₹491.90 | -1.68% | 220,715 |
| 09/11/26 | ₹500.30 | +11.13% | 1,131,247 |
| 08/11/26 | ₹450.20 | +0.82% | 6,054 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AARTIDRUGS Stock
Select your edition
All financial news and data tailored to specific country editions
